Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05040373 · ClinicalTrials.gov registry record
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
A clinical trial of Polyneuropathy and Hereditary Transthyretin-mediated (hATTR) Amyloidosis, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- 10
- Enrollment target
- 7
- Study locations
NCT05040373 is a study of Polyneuropathy and Hereditary Transthyretin-mediated (hATTR) Amyloidosis that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 10 participants. The trial reports 7 study locations across 2 states.
The verdict
NCT05040373, a study of Polyneuropathy and Hereditary Transthyretin-mediated (hATTR) Amyloidosis, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Conditions Studied
Study Locations (7)
Other
- Clinical Trial Site - Nantes
- Clinical Trial Site - Münster
- Clinical Trial Site - Pavia
- Clinical Trial Site - Groningen
- Clinical Trial Site - Lisbon
- Clinical Trial Site - Madrid
Iowa
- Clinical Trial Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2030-10-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05040373
The ClinicalTrials.gov registry entry for NCT05040373 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Polyneuropathy appearing as the primary indexed condition, and to 0 interventions.
NCT05040373 reports 7 study locations spanning 2 distinct geographic areas - top geographies include Other, Iowa.
Frequently Asked Questions
What is clinical trial NCT05040373 about?
NCT05040373 is a clinical study titled "Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program". The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
What is the current status of trial NCT05040373?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2020-08-01. Estimated completion is 2030-10-12.
What conditions does trial NCT05040373 study?
This clinical trial studies the following conditions: Polyneuropathy, Hereditary Transthyretin-mediated (hATTR) Amyloidosis.
Who is sponsoring clinical trial NCT05040373?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05040373 being conducted?
This trial has 7 study locations across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.